Associations Between ABCC2 Polymorphisms and Cisplatin Disposition and Efficacy
- 25 April 2012
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 91 (6) , 1022-1026
Abstract
ABCC2 (MRP2, cMOAT) expression has been implicated in cisplatin resistance in vitro. In mice, cisplatin disposition and toxicity were unaffected by Abcc2 knockout (Abcc2−/−). Moreover, in cancer pati...Keywords
This publication has 30 references indexed in Scilit:
- Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patientsLung Cancer, 2011
- Cisplatin-Induced Downregulation of OCTN2 Affects Carnitine WastingClinical Cancer Research, 2010
- The 5′-Untranslated Region of Multidrug Resistance Associated Protein 2 (MRP2; ABCC2) Regulates Downstream Open Reading Frame Expression through Translational RegulationMolecular Pharmacology, 2010
- Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced NephrotoxicityClinical Pharmacology & Therapeutics, 2009
- MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancerCancer Chemotherapy and Pharmacology, 2009
- Interaction of Cisplatin with the Human Organic Cation Transporter 2Clinical Cancer Research, 2008
- Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinololPharmacogenetics and Genomics, 2008
- Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan‐pharmacokinetics and clinical outcome in patients with advanced non‐small cell lung cancerCancer, 2007
- Characterization of Mice Lacking the Multidrug Resistance Protein Mrp2 (Abcc2)The Journal of Pharmacology and Experimental Therapeutics, 2006
- MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecidInternational Journal of Cancer, 2005